肝臓がん治療の世界市場レポート (2025年)

肝臓がん治療の市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR16.8％で55億米ドルに成長します。予測期間に予測される成長は、肝臓がんの世界の罹患率の増加、B型およびC型肝炎の高い有病率、アルコール関連肝疾患の増加、非アルコール性脂肪性肝疾患の症例数の増加、免疫療法アプローチの採用拡大などに起因しています。予測期間における主な動向としては、創薬におけるAIとMLの統合、臨床試験におけるビッグデータと実世界のエビデンスの活用、画像技術の進歩、低侵襲診断ツールの採用、腫瘍学のフォローアップケアにおける遠隔医療とデジタルヘルスの活用などが挙げられます。

B型肝炎感染の増加は、肝臓がん治療市場の成長を促進すると予想されます。B型肝炎は、B型肝炎ウイルス（HBV）によって引き起こされるウイルス性疾患で、主に肝臓を侵し、肝臓がんなど急性および慢性の健康問題を引き起こす可能性があります。B型肝炎感染の増加は、部分的には、汚染された注射針や注射器の共有を通じてウイルスを拡散させる注射薬の使用の増加によって促進されています。B型肝炎に慢性的に感染すると、肝臓の炎症と細胞障害が進行し、時間の経過とともに悪性肝疾患のリスクが著しく高まるため、B型肝炎感染の管理には肝臓がん治療が不可欠です。例えば、世界保健機関（WHO）が2024年4月に発表した報告書によると、2022年には世界で2億5,400万人以上がB型肝炎に罹患しており、120万人が新たにB型肝炎に罹患したと報告されています。また、B型肝炎は、全世界のウイルス性肝炎関連死130万人の83％を占めていました。その結果、B型肝炎感染の増加により、肝臓がん治療市場の成長が加速されるでしょう。

革新的治療が、特に免疫療法の進歩を通じて肝がん治療市場の成長を牽引しています。肝臓がん治療市場の主要企業は、効果が長期間持続する処方免疫療法薬などの最先端治療法の開発に注力しています。これらの医薬品は、免疫反応を標的とし、それを調節することによって、がんや慢性感染症を含む特定の疾患と闘うために、身体の免疫系を強化または抑制することによって機能します。例えば、2025年4月、米国のバイオ医薬品会社であるブリストル・マイヤーズスクイブ社は、米国食品医薬品局（FDA）が、難治性または転移性の原発性肝がんの中で最も一般的なタイプである肝細胞がん（HCC）の成人患者に対し、オプジーボ（ニボルマブ）とヤーボイ（イピリムマブ）を第一選択薬として承認したと発表しました。今回の承認は、世界で実施された第3相無作為化非盲検試験CheckMate-9DWの結果に基づくもので、全身療法を受けたことのない転移性または治癒切除不能な肝細胞がん患者を、チロシンキナーゼ阻害剤（レンバチニブまたはソラフェニブ）と併用するオプジーボ＋ヤーボイ併用療法群に無作為に割り付けたところ、全生存期間（OS）および全奏効率（ORR）が比較群に比べて統計学的に有意に改善しました。この併用療法は、この設定において優れた結果を示し、FDAの承認を支持する唯一のものでした。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場のマクロ経済シナリオ：金利・インフレ・地政学・貿易戦争・関税・コロナ禍と回復が市場に及ぼす影響を含む

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の肝臓がん治療市場：PESTEL分析（政治・社会・技術・環境・法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の肝臓がん治療市場：成長率分析
• 世界の肝臓がん治療の市場規模・成長率：実績値、2019～2024年
• 世界の肝臓がん治療の市場規模・成長率：予測値、2024～2029年、2034年
• 世界の肝臓がん治療市場：総有効市場（TAM）

第6章 市場セグメンテーション

• 世界の肝臓がん治療市場：種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 肝細胞がん
• 胆管がん
• 肝芽腫
• その他の種類
• 世界の肝臓がん治療市場：治療法の種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 標的療法
• 免疫療法
• 化学療法
• 放射線治療
• その他の治療法
• 世界の肝臓がん治療市場：流通チャネル別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の肝臓がん治療市場：エンドユーザー別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 小児
• 成人
• 世界の肝臓がん治療市場：肝細胞がんの種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 局所性肝細胞がん
• 進行肝細胞がん
• 再発性肝細胞がん
• 世界の肝臓がん治療市場：胆管がんの種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 肝内胆管がん
• 肝外胆管がん
• 門脈周囲胆管がん
• 世界の肝臓がん治療市場：肝芽腫の種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 標準リスク肝芽腫
• 高リスク肝芽腫
• 転移性肝芽腫
• 世界の肝臓がん治療市場：その他の種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 線維層がん
• 肝臓血管肉腫
• 血管肉腫

第7章 地域別・国別の分析

• 世界の肝臓がん治療市場：地域別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 世界の肝臓がん治療市場：国別、実績値・予測値、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 肝臓がん治療市場：競合情勢
• 肝臓がん治療市場：企業プロファイル
  • Pfizer Inc.（概要、製品・サービス、戦略、財務分析）
  • F. Hoffmann-La Roche Ltd.（概要、製品・サービス、戦略、財務分析）
  • Merck & Co. Inc.（概要、製品・サービス、戦略、財務分析）
  • Novartis AG（概要、製品・サービス、戦略、財務分析）
  • Bayer AG（概要、製品・サービス、戦略、財務分析）

第31章 その他の大手企業と革新的企業

• Sanofi SA
• Bristol-Myers Squibb
• AstraZeneca PLC
• Amgen Inc.
• Eli Lilly and Company
• Gilead Sciences Inc.
• Regeneron Pharmaceuticals Inc.
• Eisai Co. Ltd.
• Ipsen
• Exelixis Inc.
• BeiGene Ltd.
• Hutchmed
• Celgene Corporation
• Zymeworks Inc.
• Can-Fite BioPharma

第32章 世界市場：競合ベンチマーキング・ダッシュボード

第33章 主要な企業合併・買収 (M&A)

第34章 最近の市場動向

第35章 市場の潜在力の高い国・部門と戦略

• 肝臓がん治療市場：最新機会を提供する国（2029年）
• 肝臓がん治療市場：最新機会を提供する部門（2029年）
• 肝臓がん治療市場：成長戦略（2029年）
  • 市場動向に基づく戦略
  • 競争戦略

第36章 付録

Liver cancer therapeutics involve a range of treatments designed to manage abnormal cell growth in the liver, a vital organ responsible for essential metabolic and detoxification functions. These therapies aim to target, control, or eradicate harmful cellular activity while preserving as much healthy tissue as possible.

The main types of liver cancer therapeutics include treatments for hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and other liver cancers. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, originating in the liver's hepatocytes (the primary liver cells). It is a leading cause of cancer-related deaths worldwide, especially in regions with high rates of chronic liver diseases including hepatitis B, hepatitis C, alcohol-related liver disease, and cirrhosis (liver scarring). Treatments for HCC include targeted therapy, immunotherapy, chemotherapy, radiation therapy, and others. These therapies are available through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by a wide range of patients, including both adults and children.

The liver cancer therapeutics market research report is one of a series of new reports from The Business Research Company that provides liver cancer therapeutics market statistics, including liver cancer therapeutics industry global market size, regional shares, competitors with a liver cancer therapeutics market share, detailed liver cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the liver cancer therapeutics industry. This liver cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liver cancer therapeutics market size has grown rapidly in recent years. It will grow from $2.52 billion in 2024 to $2.95 billion in 2025 at a compound annual growth rate (CAGR) of 17.1%. The growth observed in the historical period can be attributed to higher funding from government and non-profit organizations, rising global healthcare spending, expanding health insurance coverage in developing nations, an aging global population, and the increasing prevalence of obesity and diabetes.

The liver cancer therapeutics market size is expected to see rapid growth in the next few years. It will grow to $5.50 billion in 2029 at a compound annual growth rate (CAGR) of 16.8%. The growth projected for the forecast period can be attributed to the increasing global incidence of liver cancer, the high prevalence of hepatitis B and C infections, the rise in alcohol-related liver disease, a growing number of non-alcoholic fatty liver disease cases, and the expanding adoption of immunotherapy approaches. Key trends in the forecast period include the integration of AI and ML in drug discovery, the use of big data and real-world evidence in clinical trials, advancements in imaging technologies, the adoption of minimally invasive diagnostic tools, and the use of telemedicine and digital health in oncology follow-up care.

The increasing incidence of hepatitis B infections is expected to drive the growth of the liver cancer therapeutics market. Hepatitis B is a viral disease caused by the hepatitis B virus (HBV), primarily affecting the liver and potentially leading to both acute and chronic health issues, including liver cancer. The rise in hepatitis B infections is partially fueled by the growing use of injection drugs, which spread the virus through the sharing of contaminated needles and syringes. Liver cancer therapeutics are essential for managing hepatitis B infections, as chronic infection can result in ongoing liver inflammation and cellular damage, significantly raising the risk of malignant liver conditions over time. For example, a report published by the World Health Organization (WHO) in April 2024 indicated that in 2022, over 254 million people globally were living with hepatitis B, with 1.2 million new cases recorded. Hepatitis B was also responsible for 83% of the 1.3 million viral hepatitis-related deaths worldwide. Consequently, the rising incidence of hepatitis B infections will accelerate the growth of the liver cancer therapeutics market.

Innovative therapies are driving growth in the liver cancer treatment market, particularly through advancements in immunotherapy. Leading companies in the liver cancer therapeutics market are focusing on developing cutting-edge treatments, such as prescription immunotherapy drugs, to offer long-lasting effects. These medications work by enhancing or suppressing the body's immune system to fight specific diseases, including cancer or chronic infections, by targeting and modulating immune responses. For example, in April 2025, Bristol Myers Squibb, a U.S.-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Opdivo (nivolumab) and Yervoy (ipilimumab) for adult patients with hepatocellular carcinoma (HCC), the most common type of primary liver cancer, either incurable or metastatic, as a first-line treatment. The approval was based on the results of the global Phase 3 randomized, open-label CheckMate-9DW trial, which showed that patients with metastatic or incurable HCC who had not previously received systemic therapy and were randomized to receive Opdivo plus Yervoy along with a tyrosine kinase inhibitor (lenvatinib or sorafenib) experienced statistically significant improvements in overall survival (OS) and overall response rate (ORR) compared to the comparator group. This combination therapy was the only one supporting an FDA approval with superior results in this setting.

In September 2023, Coherus BioSciences Inc., a U.S.-based biopharmaceutical company, acquired Surface Oncology Inc. for an undisclosed amount. This acquisition strengthens Coherus' immuno-oncology pipeline, which now includes four distinct clinical-stage assets toripalimab (anti-PD-1), casdozokitug (IL-27-targeted), CHS-114 (CCR8-targeted), and CHS-006 (TIGIT-targeted). The focus of development will be on achieving breakthrough survival benefits for cancer patients, aiming to surpass the efficacy of current chemotherapy combined with checkpoint inhibitor regimens. Surface Oncology Inc. is a US-based company, focusing on developing therapeutics for liver cancer.

Major players in the liver cancer therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca PLC, Amgen Inc., Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Ipsen, Exelixis Inc., BeiGene Ltd., Hutchmed, Celgene Corporation, Zymeworks Inc., Can-Fite BioPharma, and Onyx Pharmaceuticals Inc.

North America was the largest region in the liver cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in liver cancer therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the liver cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The liver cancer therapeutics market consists of revenues earned by entities by providing services such as diagnostics and screening, personalized treatment planning, minimally invasive procedures, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer therapeutics market also includes sales of drug delivery systems, diagnostic kits, biologics and supportive medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liver Cancer Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liver cancer therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liver cancer therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The liver cancer therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Hepatocellular Carcinoma; Cholangio Carcinoma; Hepatoblastoma; Other Types
• 2) By Therapy Type: Targeted Therapy; Immunotherapy; Chemotherapy; Radiation Therapy; Other Therapy Types
• 3) By Distribution Channel Type: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 4) By End-Users: Pediatrics; Adults
• Subsegments:
• 1) By Hepatocellular Carcinoma: Localized Hepatocellular Carcinoma; Advanced Hepatocellular Carcinoma; Recurrent Hepatocellular Carcinoma
• 2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma; Perihilar Cholangiocarcinoma
• 3) By Hepatoblastoma: Standard-Risk Hepatoblastoma; High-Risk Hepatoblastoma; Metastatic Hepatoblastoma
• 4) By Other Types: Fibrolamellar Carcinoma; Angiosarcoma Of The Liver; Hemangiosarcoma
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Liver Cancer Therapeutics Market Characteristics

3. Liver Cancer Therapeutics Market Trends And Strategies

4. Liver Cancer Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Liver Cancer Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Liver Cancer Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Liver Cancer Therapeutics Market Growth Rate Analysis
• 5.4. Global Liver Cancer Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Liver Cancer Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Liver Cancer Therapeutics Total Addressable Market (TAM)

6. Liver Cancer Therapeutics Market Segmentation

• 6.1. Global Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatocellular Carcinoma
• Cholangio Carcinoma
• Hepatoblastoma
• Other Types
• 6.2. Global Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Radiation Therapy
• Other Therapy Types
• 6.3. Global Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.4. Global Liver Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatrics
• Adults
• 6.5. Global Liver Cancer Therapeutics Market, Sub-Segmentation Of Hepatocellular Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Localized Hepatocellular Carcinoma
• Advanced Hepatocellular Carcinoma
• Recurrent Hepatocellular Carcinoma
• 6.6. Global Liver Cancer Therapeutics Market, Sub-Segmentation Of Cholangiocarcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intrahepatic Cholangiocarcinoma
• Extrahepatic Cholangiocarcinoma
• Perihilar Cholangiocarcinoma
• 6.7. Global Liver Cancer Therapeutics Market, Sub-Segmentation Of Hepatoblastoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard-Risk Hepatoblastoma
• High-Risk Hepatoblastoma
• Metastatic Hepatoblastoma
• 6.8. Global Liver Cancer Therapeutics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fibrolamellar Carcinoma
• Angiosarcoma Of The Liver
• Hemangiosarcoma

7. Liver Cancer Therapeutics Market Regional And Country Analysis

• 7.1. Global Liver Cancer Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Liver Cancer Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Liver Cancer Therapeutics Market

• 8.1. Asia-Pacific Liver Cancer Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Liver Cancer Therapeutics Market

• 9.1. China Liver Cancer Therapeutics Market Overview
• 9.2. China Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Liver Cancer Therapeutics Market

• 10.1. India Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Liver Cancer Therapeutics Market

• 11.1. Japan Liver Cancer Therapeutics Market Overview
• 11.2. Japan Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Liver Cancer Therapeutics Market

• 12.1. Australia Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Liver Cancer Therapeutics Market

• 13.1. Indonesia Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Liver Cancer Therapeutics Market

• 14.1. South Korea Liver Cancer Therapeutics Market Overview
• 14.2. South Korea Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Liver Cancer Therapeutics Market

• 15.1. Western Europe Liver Cancer Therapeutics Market Overview
• 15.2. Western Europe Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Liver Cancer Therapeutics Market

• 16.1. UK Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Liver Cancer Therapeutics Market

• 17.1. Germany Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Liver Cancer Therapeutics Market

• 18.1. France Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Liver Cancer Therapeutics Market

• 19.1. Italy Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Liver Cancer Therapeutics Market

• 20.1. Spain Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Liver Cancer Therapeutics Market

• 21.1. Eastern Europe Liver Cancer Therapeutics Market Overview
• 21.2. Eastern Europe Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Liver Cancer Therapeutics Market

• 22.1. Russia Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Liver Cancer Therapeutics Market

• 23.1. North America Liver Cancer Therapeutics Market Overview
• 23.2. North America Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Liver Cancer Therapeutics Market

• 24.1. USA Liver Cancer Therapeutics Market Overview
• 24.2. USA Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Liver Cancer Therapeutics Market

• 25.1. Canada Liver Cancer Therapeutics Market Overview
• 25.2. Canada Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Liver Cancer Therapeutics Market

• 26.1. South America Liver Cancer Therapeutics Market Overview
• 26.2. South America Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Liver Cancer Therapeutics Market

• 27.1. Brazil Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Liver Cancer Therapeutics Market

• 28.1. Middle East Liver Cancer Therapeutics Market Overview
• 28.2. Middle East Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Liver Cancer Therapeutics Market

• 29.1. Africa Liver Cancer Therapeutics Market Overview
• 29.2. Africa Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Liver Cancer Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Liver Cancer Therapeutics Market Competitive Landscape
• 30.2. Liver Cancer Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Liver Cancer Therapeutics Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. Bristol-Myers Squibb
• 31.3. AstraZeneca PLC
• 31.4. Amgen Inc.
• 31.5. Eli Lilly and Company
• 31.6. Gilead Sciences Inc.
• 31.7. Regeneron Pharmaceuticals Inc.
• 31.8. Eisai Co. Ltd.
• 31.9. Ipsen
• 31.10. Exelixis Inc.
• 31.11. BeiGene Ltd.
• 31.12. Hutchmed
• 31.13. Celgene Corporation
• 31.14. Zymeworks Inc.
• 31.15. Can-Fite BioPharma

32. Global Liver Cancer Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Liver Cancer Therapeutics Market

34. Recent Developments In The Liver Cancer Therapeutics Market

35. Liver Cancer Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Liver Cancer Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Liver Cancer Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Liver Cancer Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer